CoChat

A randomized Phase I study of the safety, tolerability, pharmacokinetics and pharmacodynamics of BI 456906, a dual glucagon receptor/glucagon‐like peptide‐1 receptor agonist, in healthy Japanese men with overweight/obesity

Open access
Yazawa, Rie, Ishida, Masahiro, Balavarca, Yesilda, Hennige, Anita M. · 2023 · Diabetes, Obesity and Metabolism
Cited by 23

The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.

Abstract

Aim: To report a Phase I study of subcutaneous glucagon receptor (GCGR)/glucagon‐like peptide‐1 receptor (GLP‐1R) dual agonist BI 456906 versus placebo in healthy Japanese men with overweight/obesity. Materials and methods: We investigated multiple rising doses of BI 456906 escalated over 16 weeks (maximum doses: 1.8 mg once weekly [dose group {DG} 1], 4.8 mg once weekly [DG 2] and 2.4 mg twice weekly [DG 3]) in Japanese men with a body mass index of 23 to 40 kg/m 2 . Results: Thirty‐six participants were treated (n = 9 per DG and placebo). Overall, 10 participants (37.0%) treated with BI 456906 withdrew from dose escalation due to adverse events (amylase increase, n = 1; decreased appetite, n = 9), and the proportion of participants was higher in DG 2 (n = 6, 66.7%) versus DGs 1 and 3 (both n = 2, 22.2%). No participants receiving placebo withdrew from dose escalation. BI 456906 exposure increased with dose and dose escalation in each DG. Treatment with BI 456906 decreased placebo‐corrected bodyweight after 16 weeks (placebo +1.06%): DG 1, −5.57%; DG 2, −12.37%; DG 3, −9.62%. Paracetamol absorption decreased in Week 1 for DGs 2 and 3, indicating transient delayed gastric emptying. BI 456906 reduced plasma alanine and glucagon levels, indicating indirect target engagement at GCGRs and GLP‐1Rs. Drug‐related adverse events were reported for all participants receiving BI 456906 and four receiving placebo, the most frequent being decreased appetite (n = 24, 66.7%). Conclusions: BI 456906 showed no unexpected tolerability concerns and it reduced placebo‐corrected bodyweight by up to 12.37% in Japanese men with overweight/obesity after 16 weeks of treatment.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/dom.15064

Cites

25 of 25 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 22

  1. World Health Organization, 2021, Fact Sheet on Obesity and Overweight
  2. 10.1016/S0140-6736(03)15268-3 · DOI · Paper page
  3. 10.1159/000088200 · DOI · Paper page
  4. 10.1016/j.jacc.2013.11.004 · DOI · Paper page
  5. Australian Department of Health National Health and Medical Research Council, 2013, Clinical Practice Guidelines for the Management of Overweight and Obesity in Adults, Adolescents and Children in Australia
  6. 10.1159/000442721 · DOI · Paper page
  7. 10.1038/s41574-018-0118-x · DOI
  8. 10.1111/jdi.12464 · DOI · Paper page
  9. 10.21037/atm.2019.01.09 · DOI
  10. 10.1016/S0140-6736(18)31773-2 · DOI · Paper page
  11. 10.1111/dom.12932 · DOI · Paper page
  12. U.S. Food & Drug Administration, FDA Approves New Drug Treatment for Chronic Weight Management, First since 2014
  13. U.S. Food & Drug Administration, 2020, FDA Approves Weight Management Drug for Patients Aged 12 and Older
  14. 10.2337/db09-0278 · DOI · Paper page
  15. 10.2337/db12-0797 · DOI · Paper page
  16. 10.1152/ajpendo.00576.2007 · DOI · Paper page
  17. 10.1210/en.2003-1338 · DOI · Paper page
  18. 10.1111/dom.14496 · DOI · Paper page
  19. 10.1111/dom.14572 · DOI · Paper page
  20. 10.1136/bmjdrc-2021-002208 · DOI
  21. 10.1111/j.1463-1326.2012.01557.x · DOI · Paper page
  22. Rosenstock J, 2022, SO46 613 multiple dose‐ranging study of the novel glucagon/GLP‐1 receptor dual agonist BI 456906 vs placebo and open‐label weekly semaglutide reference control in type 2 diabetes, Diabetologia, 65, S314

Cited by

See all 23

Metadata

Authors
Yazawa, R., Ishida, M., Balavarca, Y., & Hennige, A. M.
Venue
Diabetes, Obesity and Metabolism
Publisher
Wiley
Published
2023-04-27
Volume
25
Issue
7
Pages
1973-1984
ISSN
  • 1462-8902 (ISSN-L)
  • 1463-1326
OpenAlex
W4361190240
Cited by
23
References
25
FWCI
2.94
Type
journal article
Language
en
Open access
hybrid
Funders
Boehringer Ingelheim

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.